The safety of phosphodiesterase type 5 inhibitors for erectile dysfunction
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The safety of phosphodiesterase type 5 inhibitors for erectile dysfunction
Authors
Keywords
-
Journal
Expert Opinion On Drug Safety
Volume 15, Issue 2, Pages 141-152
Publisher
Informa Healthcare
Online
2015-12-12
DOI
10.1517/14740338.2016.1131818
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Tadalafil in the treatment of erectile dysfunction
- (2016) Robert Coward et al. Therapeutics and Clinical Risk Management
- A Detailed Analysis of the Association Between Postoperative Phosphodiesterase Type 5 Inhibitor Use and the Risk of Biochemical Recurrence After Radical Prostatectomy
- (2015) Andrea Gallina et al. EUROPEAN UROLOGY
- Phosphodiesterase 5 Inhibitors for the Treatment of Erectile Dysfunction: A Trade-off Network Meta-analysis
- (2015) Liang Chen et al. EUROPEAN UROLOGY
- Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma
- (2015) Stacy Loeb et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Efficacy of Avanafil 15 Minutes after Dosing in Men with Erectile Dysfunction: A Randomized, Double-Blind, Placebo Controlled Study
- (2015) Wayne J.G. Hellstrom et al. JOURNAL OF UROLOGY
- Use of Phosphodiesterase Type 5 Inhibitors May Adversely Impact Biochemical Recurrence after Radical Prostatectomy
- (2015) Uwe Michl et al. JOURNAL OF UROLOGY
- Pharmacokinetics of a Novel Orodispersible Tablet of Sildenafil in Healthy Subjects
- (2014) Bharat Damle et al. CLINICAL THERAPEUTICS
- Sildenafil Use and Increased Risk of Incident Melanoma in US Men
- (2014) Wen-Qing Li et al. JAMA Internal Medicine
- Oral Phosphodiesterase-5 Inhibitors and Hormonal Treatments for Erectile Dysfunction: A Systematic Review and Meta-analysis
- (2013) Alexander Tsertsvadze et al. ANNALS OF INTERNAL MEDICINE
- Pharmacokinetic Comparison of an Orally Disintegrating Film Formulation With a Film-Coated Tablet Formulation of Sildenafil in Healthy Korean Subjects: A Randomized, Open-Label, Single-Dose, 2-Period Crossover Study
- (2013) Hyerang Roh et al. CLINICAL THERAPEUTICS
- Comparative Effectiveness and Safety of Oral Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction: A Systematic Review and Network Meta-analysis
- (2013) JinQiu Yuan et al. EUROPEAN UROLOGY
- An open-label, long-term evaluation of the safety, efficacy and tolerability of avanafil in male patients with mild to severe erectile dysfunction
- (2013) L. H. Belkoff et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- PDE5 inhibitors: considerations for preference and long-term adherence
- (2013) W. B. Smith et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Adherence to Initial PDE5 Inhibitor Treatment: Randomized OpenLabel Study Comparing Tadalafil Once a Day, Tadalafil on Demand, and Sildenafil on Demand in Patients with Erectile Dysfunction
- (2013) Jacques Buvat et al. Journal of Sexual Medicine
- SOP Conservative (Medical and Mechanical) Treatment of Erectile Dysfunction
- (2013) Hartmut Porst et al. Journal of Sexual Medicine
- Efficacy and safety of avanafil for treating erectile dysfunction: results of a multicentre, randomized, double-blind, placebo-controlled trial
- (2012) Chen Zhao et al. BJU INTERNATIONAL
- PDE5 inhibitor promotes melanin synthesis through the PKG pathway in B16 melanoma cells
- (2012) Xiaodong Zhang et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Selectivity of Avanafil, a PDE5 Inhibitor for the Treatment of Erectile Dysfunction: Implications for Clinical Safety and Improved Tolerability
- (2012) Run Wang et al. Journal of Sexual Medicine
- A Randomized, Double‐Blind, Placebo‐Controlled Evaluation of the Safety and Efficacy of Avanafil in Subjects with Erectile Dysfunction
- (2012) Irwin Goldstein et al. Journal of Sexual Medicine
- Safety and Efficacy of Once Daily Administration of 50 mg Mirodenafil in Patients with Erectile Dysfunction: a Multicenter, Double-Blind, Placebo Controlled Trial
- (2012) Jae Hoon Chung et al. JOURNAL OF UROLOGY
- Avanafil for the Treatment of Erectile Dysfunction: A Multicenter, Randomized, Double-Blind Study in Men With Diabetes Mellitus
- (2012) Irwin Goldstein et al. MAYO CLINIC PROCEEDINGS
- The Princeton III Consensus Recommendations for the Management of Erectile Dysfunction and Cardiovascular Disease
- (2012) Ajay Nehra et al. MAYO CLINIC PROCEEDINGS
- cGMP-Prkg1 signaling and Pde5 inhibition shelter cochlear hair cells and hearing function
- (2012) Mirko Jaumann et al. NATURE MEDICINE
- Vardenafil Orodispersible Tablet
- (2011) Mark Sanford DRUGS
- Efficacy and Safety of Once-Daily Dosing of Udenafil in the Treatment of Erectile Dysfunction: Results of a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
- (2011) Chen Zhao et al. EUROPEAN UROLOGY
- Time to Onset of Action of Vardenafil: A Retrospective Analysis of the Pivotal Trials for the Orodispersible and Film‐Coated Tablet Formulations
- (2011) Frans M.J. Debruyne et al. Journal of Sexual Medicine
- A Randomized, Double‐Blind, Placebo‐Controlled, Parallel Study to Assess the Efficacy and Safety of Once‐A‐Day Tadalafil in Men with Erectile Dysfunction Who Are Naïve to PDE5 Inhibitors
- (2011) Francesco Montorsi et al. Journal of Sexual Medicine
- Are Phosphodiesterase Type 5 Inhibitors Associated with Vision‐Threatening Adverse Events? A Critical Analysis and Review of the Literature
- (2011) Faris Azzouni et al. Journal of Sexual Medicine
- 10‐Year Analysis of Adverse Event Reports to the Food and Drug Administration for Phosphodiesterase Type‐5 Inhibitors
- (2011) Gregory Lowe et al. Journal of Sexual Medicine
- A new era in the treatment of erectile dysfunction: chronic phosphodiesterase type 5 inhibition
- (2010) Ferdinando Fusco et al. BJU INTERNATIONAL
- The POTENT II randomised trial: efficacy and safety of an orodispersible vardenafil formulation for the treatment of erectile dysfunction
- (2010) M. Gittelman et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Pharmacotherapy for Erectile Dysfunction
- (2010) Ian Eardley et al. Journal of Sexual Medicine
- The POTENT I Randomized Trial: Efficacy and Safety of an Orodispersible Vardenafil Formulation for the Treatment of Erectile Dysfunction
- (2010) Herbert Sperling et al. Journal of Sexual Medicine
- Efficacy and Safety of Oral Mirodenafil in the Treatment of Erectile Dysfunction in Diabetic Men in Korea: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial
- (2010) Hyun Jun Park et al. Journal of Sexual Medicine
- ORIGINAL RESEARCH—ED PHARMACOTHERAPY: Efficacy and Tolerability of Lodenafil Carbonate for Oral Therapy of Erectile Dysfunction: A Phase III Clinical Trial
- (2010) Sidney Glina et al. Journal of Sexual Medicine
- Efficacy and Safety of an Orodispersible Vardenafil Formulation for the Treatment of Erectile Dysfunction in Elderly Men and Those with Underlying Conditions: An Integrated Analysis of Two Pivotal Trials
- (2010) Herbert Sperling et al. Journal of Sexual Medicine
- Tadalafil once daily in the management of erectile dysfunction: patient and partner perspectives
- (2010) Pierre Costa et al. Patient Preference and Adherence
- Differences in side-effect duration and related bother levels between phosphodiesterase type 5 inhibitors
- (2009) Joby Taylor et al. BJU INTERNATIONAL
- Phosphodiesterase inhibitors and the eye
- (2009) Nathan M Kerr et al. CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
- PDE5 Inhibitors: In Vitro and In Vivo Pharmacological Profile
- (2009) D. Kouvelas et al. CURRENT PHARMACEUTICAL DESIGN
- Safety of sildenafil citrate: review of 67 double-blind placebo-controlled trials and the postmarketing safety database
- (2009) F. Giuliano et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Safety, Efficacy, and Pharmacokinetic Overview of Low-Dose Daily Administration of Tadalafil
- (2009) Rebecca Wrishko et al. Journal of Sexual Medicine
- Likelihood of Tadalafil-associated Adverse Events in Integrated Multiclinical Trial Database: Classification Tree Analysis in Men With Erectile Dysfunction
- (2009) Gerald Brock et al. UROLOGY
- Oral Sildenafil Citrate (Viagra) for Erectile Dysfunction: A Systematic Review and Meta-analysis of Harms
- (2009) Alexander Tsertsvadze et al. UROLOGY
- High Dosage Sildenafil Induces Hearing Impairment in Mice
- (2008) Bin Na Hong et al. BIOLOGICAL & PHARMACEUTICAL BULLETIN
- Efficacy and safety of tadalafil once daily: considerations for the practical application of a daily dosing option
- (2008) Craig F. Donatucci et al. CURRENT MEDICAL RESEARCH AND OPINION
- Pharmacological characterization of a novel phosphodiesterase type 5 (PDE5) inhibitor lodenafil carbonate on human and rabbit corpus cavernosum
- (2008) Haroldo A. Toque et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- ORIGINAL RESEARCH—ED PHARMACOTHERAPY: Efficacy and Safety of Mirodenafil, A New Oral Phosphodiesterase Type 5 Inhibitor, for Treatment of Erectile Dysfunction
- (2008) Jae‐Seung Paick et al. Journal of Sexual Medicine
- The Efficacy and Safety of Udenafil, a New Selective Phosphodiesterase Type 5 Inhibitor, in Patients with Erectile Dysfunction
- (2008) Jae-Seung Paick et al. Journal of Sexual Medicine
- Efficacy and Tolerability of Lodenafil Carbonate for Oral Therapy in Erectile Dysfunction: A Phase II Clinical Trial
- (2008) Sidney Glina et al. Journal of Sexual Medicine
- An Evaluation of Semen Characteristics in Men 45 Years of Age or Older after Daily Dosing with Tadalafil 20mg: Results of a Multicenter, Randomized, Double-Blind, Placebo-Controlled, 9-Month Study
- (2007) Wayne J.G. Hellstrom et al. EUROPEAN UROLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started